Journal of Clinical Microbiology and Antimicrobials
Open Access

Department of Clinical Pharmacology, HCG Cancer Hospital, Bangalore, India

Publications

• Research Article   
  Meropenem Versus Ceftazidime-Avibactam Versus Ceftazidime-Avibactam with Aztreonam as Empiric, First-Line Treatment of High-Risk Febrile Neutropenia: First Report of the CAMerA Trial, an Open-Labelled, Randomized-Controlled Trial
  Author(s): Sachin Suresh Jadhav*, Jyothi Goutham Kumar, Anjali Matani, Amey C Panchal, Nishit Ojha, Sonu Tony and Yesheswini N Naik
  
  Introduction: Infections due to Extended Spectrum Beta-Lactam (ESBL) positive, Carbapenemase Producing Enterobacteriaceae (CPE) and NDM1 resistance Enterobacteriaceae have significantly increased internationally and may account for up to 70% of infections in some geographies. Parallelly, high colistin resistance rates have also been reported. We are reporting the initial results of the first randomized-controlled trial addressing this issue of antibiotic resistant Gram-Negative Bacteremia (GNB). Objectives: The objective of the study was to assess the efficacy of first-line Ceftazidime–Avibactam with or without Aztreonam in high-risk FN, versus Meropenem. Methodology: Adult patients with high-risk FN were randomized to Meropenem, Ceftazidime-Avibactum or Ceftazidime-Avibactum with Aztreonam as the fi.. View More»
  DOI: 10.35248/jcma.24.8.179

  Abstract HTML PDF